All In Biotech

Drug Trial Radar · NCT03981523

New Therapies and Biomarkers for Chagas Infection

New Chemotherapy Regimens and Biomarkers for Chagas Disease

Last checked: Nov 20, 2026Latest source record: Jul 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

450

Actual

Start

Dec 18, 2019

Primary completion

May 29, 2024

Study completion May 31, 2024

Sponsor

Lead sponsor
University of Texas, El PasoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES); Barcelona Institute for Global Health; Institute of Parasitology and Biomedicine Lopez Neyra; Food and Drug Administration (FDA); Drugs for Neglected Diseases; Mundo Sano Foundation; National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Jun 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chagas disease (CD) is an endemic zoonotic disease with a significant global impact. Current approved treatments for CD (benznidazole (BZN) and nifurtimox (NFX)) were developed in the 1970s with regimens and dosing intervals derived from decades-old patient series and with very limited direct comparisons. Treatment recommendations vary significantly from country to country and the comparative evidence-base with the current treatment regimens is limited. The reported efficacy of both drugs in patients with T. cruzi infection is variable and depends on the disease stage, the drug dose, the age of patients, and the infecting T. cruzi strain or genotype. Due to a therapeutic failure of at least 20% after 12 months in chronic patients and the high rate of adverse events, together with the recent data that suggest that we may be overdosing patients, we propose to test new dosing regimens of these two old compounds. Hypotheses: * Lowering the frequency of drug dosing of BZN and NFX, the plasma drug levels of the drugs within the therapeutic range will be maintained. * The duration of treatment with BZN or NFX may be related to the effectiveness of these drugs. * Blood levels of the proposed biomarkers will significantly diminish or became negative after a relatively short interval after treatment.

Conditions

  • Trypanosoma Cruzi Infection
  • Chagas Disease

Interventions

  • BenznidazoleDrug

    50 mg and 100 mg tablet taken orally

  • NifurtimoxDrug

    120 mg tablet taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sustained Parasitological Clearance by qPCR at End of Follow-Up (36 months)Time frame: up to 36 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Platform for the Comprehensive Care of Patients with Chagas Disease

    Sucre, Bolivia

  • Platform for the Comprehensive Care of Patients with Chagas Disease

    Cochabamba, Cercado, Bolivia

  • Platform for the Comprehensive Care of Patients with Chagas Disease

    Tarija, Cercado, Bolivia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.